References
- Bansal AD, Hill CE, Berns JS. (2015). Use of Antiepileptic drugs in patients with chronic kidney disease and end stage renal disease. Semin Dial 28:404–12
- Benjamin B, Sahu M, Bhatnagar U, et al. (2012). The observed correlation between in vivo clinical pharmacokinetic parameters and in vitro potency of VEGFR-2 inhibitors. Can this be used as a prospective guide for the development of novel compounds? Arzneimittelforschung 62:194–201
- Benziger DP, Balfour K, Clemans S, Edelson J. (1977). Absorption, excretion and disposition of cyclindole in laboratory animals and human volunteers. Drug Metab Dispos 5:239–45
- Cabana BE, van Harken DR, Hottendorf GH. (1976). Comparative pharmacokinetics and metabolism of cephapirin in laboratory animals and humans. Antimicrob Agents Chemother 10:307–17
- Hall C, Mošat A, Lueshen E, Linninger A. (2012). Interspecies scaling in pharmacokinetics: a novel whole-body physiologically based modeling framework to discover drug biodistribution mechanisms in vivo. J Pharm Sci 101:1221–41
- Hopkins R, Martin LE, Bland R. (1976). The metabolism of labetalol in animals and man. Biochem Soc Trans 4:726–9
- Klotz U. (2009). Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev 41:67–76
- Mamidi RN, Mannens G, Annaert P, et al. (2007). Metabolism and excretion of RWJ-333369 [1,2-ethanediol, 1-(2-chlorophenyl)-, 2-carbamate, (S)-] in mice, rats, rabbits, and dogs. Drug Metab Dispos 35:566–77
- Mannens GS, Hendrickx J, Janssen CG, et al. (2007). The absorption, metabolism, and excretion of the novel neuromodulator RWJ-333369 (1,2-ethanediol, [1-2-chlorophenyl]-, 2-carbamate, [S]-) in humans. Drug Metab Dispos 35:554–65
- Mattiuz E, Franklin R, Gillespie T, et al. (1997). Disposition and metabolism of olanzapine in mice, dogs, and rhesus monkeys. Drug Metab Dispos 25:573–83
- Ramji JV, Keogh JP, Blake TJ, et al. (1999). Disposition of ropinirole in animals and man. Xenobiotica 29:311–25
- Reeve E, Wiese MD, Mangoni AA. (2015). Alterations in drug disposition in older adults. Expert Opin Drug Metab Toxicol 11:491–508
- Riska PS, Joseph DP, Dinallo RM, et al. (1999a). Biotransformation of nevirapine, a non-nucleoside HIV-1 reverse transcriptase inhibitor, in mice, rats, rabbits, dogs, monkeys, and chimpanzees. Drug Metab Dispos 27:1434–47
- Riska P, Lamson M, Mac Gregor T, et al. (1999b). Disposition and biotransformation of the antiretroviral drug nevirapine in humans. Drug Metab Dispos 27:895–901
- Roffey SJ, Cole S, Comby P, et al. (2003). The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human. Drug Metab Dispos 31:731–41
- Shi S, Klotz U. (2011). Age-related changes in pharmacokinetics. Curr Drug Metab 12:601–10
- Srinivas NR. (2015a). Interspecies scaling of excretory amounts using allometry – retrospective analysis with rifapentine, aztreonam, carumonam, pefloxacin, miloxacin, trovafloxacin, doripenem, imipenem, cefozopran, ceftazidime, linezolid for urinary excretion and rifapentine, cabotegravir, and dolutegravir for fecal excretion. Xenobiotica. [Epub ahead of print]. DOI: 10.3109/00498254.2015.1121554
- Srinivas NR. (2015b). Therapeutic drug monitoring of cyclosporine and area under the curve prediction using a single time point strategy: appraisal using peak concentration data. Biopharm Drug Dispos 29:575–86
- Srinivas NR. (2015c). Differences in the prediction of area under the curve for a protease inhibitor using trough versus peak concentration: assessment using published pharmacokinetic data for indinavir. Am J Ther. [Epub ahead of print]. doi: 10.1097/MJT.0000000000000294
- Srinivas NR. (2015d). Prediction of area under the curve for a P-glycoprotein, a CYP3A4 and a CYP2C9 substrate using a single time point strategy: assessment using fexofenadine, itraconazole and losartan and metabolites. Drug Dev Ind Pharm 15:1–13
- Srinivas NR. (2016). Limited sampling strategy for the prediction of area under the curve (AUC) of statins: reliability of a single time point for AUC prediction for pravastatin and simvastatin. Drug Res (Stuttg) 66:82–93
- Velenosi TJ, Urquhart BL. (2014). Pharmacokinetic considerations in chronic kidney disease and patients requiring dialysis. Expert Opin Drug Metab Toxicol 10:1131–43
- Weir MR, Fink JC. (2014). Safety of medical therapy in patients with chronic kidney disease and end-stage renal disease. Curr Opin Nephrol Hypertens 23:306–13
- Xeljanz® (tofacitinib product information). Available at: http://ra.xeljanz.com [last accessed 1 Feb 2016]
- Zyprexa® (olanzapine product information). Available at: http://pi.lilly.com/us/zyprexa-pi.pdf [last accessed 1 Feb 2016]